Targeted Cancer Treatments: KRASG12C

Molecular diagnosis allows us to identify genetic alterations in the tumour and offer
each patient the specific treatment for their particular type of cancer, with better
results in controlling the disease and fewer side effects.

Lung cancers with KRAS G12C mutations usually do not respond well to standard
treatments. Treatments for this type of tumour are currently being investigated in
clinical trials.

The UOMI Cancer Centre has enrolled the first patient in an international clinical trial
designed to evaluate the safety and efficacy of combining cetuximab with a KRASG12C
inhibitor.

The study drug is designed to specifically block the proteins made by the KRAS gene,
selectively inhibiting the growth of cancer cells without affecting other cells in the
body, and is therefore expected to be a more effective treatment with less toxicity.